Major nonprofit hospital systems are exploiting a federal drug discount program designed for the poor, driving up prescription costs for everyone while pocketing billions in profits.
Story Highlights
- The 340B program meant to help low-income patients has become a $66.3 billion profit engine for wealthy hospital systems
- Hospitals buy drugs at steep discounts but bill insurers and government programs at full price, keeping the difference
- Kansas lawmakers are debating legislation that would expand this exploitation to more hospitals statewide
- Federal watchdogs have repeatedly documented abuse and lack of oversight in the program
Federal Program Hijacked by Hospital Giants
The 340B Drug Pricing Program, established in 1992 to help safety-net providers serve vulnerable populations, has been transformed into a massive profit scheme by large nonprofit hospital systems. Originally designed to require drug manufacturers to sell medications at steep discounts to clinics serving the poor and uninsured, the program now funnels billions to wealthy hospitals that exploit loopholes to maximize revenue rather than help patients.
Hospital systems acquire drugs at discounted rates through 340B but continue billing insurers and government programs at full market prices, pocketing the substantial difference. This practice directly contradicts the program’s original intent and undermines the free market principles that should govern healthcare pricing. The Affordable Care Act accelerated this abuse by expanding eligibility criteria and encouraging hospital consolidation.
“Hospitals buy drugs cheap, bill high, and pocket the profits. Those profits fund expansion — not lower costs for patients. The lure of easy money drives hospital consolidation across the country.” https://t.co/WD0BT7bUqr
— -ʙᴇᴢɪǫᴜᴇ x- (@BeziqueOnX) October 17, 2025
Kansas Legislation Threatens to Worsen the Crisis
Kansas lawmakers are currently debating Senate Bill 284, which would expand hospital access to 340B discounts and restrict drug manufacturers’ ability to control program abuse. This proposed legislation exemplifies how state governments often enable corporate welfare at taxpayers’ expense. The bill would allow more hospitals to exploit the program while removing safeguards that manufacturers use to prevent misuse of discounted medications.
Federal watchdogs from the Government Accountability Office and Office of Inspector General have repeatedly documented the lack of transparency and oversight in 340B operations. Despite these warnings, state legislators continue pushing expansion that benefits large hospital corporations rather than the patients the program was designed to serve. This represents a clear example of crony capitalism undermining genuine healthcare reform.
Watch a report:
Market Consolidation Destroys Competition
The 340B program’s current structure accelerates dangerous market consolidation that eliminates competition and reduces patient choice. Large hospital systems use their 340B profits to acquire independent clinics and smaller providers, creating healthcare monopolies in many regions. This consolidation particularly harms rural communities, where independent providers often serve as the primary source of medical care.
When hospitals acquire outpatient clinics and declare them 340B-eligible regardless of patient demographics, they destroy competitive pricing mechanisms that would naturally reduce healthcare costs. Small clinics and independent providers cannot compete with hospital systems that receive massive government subsidies disguised as charity care programs. This government interference in healthcare markets contradicts conservative principles of free enterprise and limited government.
Sources:
The hidden hospital scam driving up drug prices, coming to a state near you
Prescription for sanity: Ending the great American drug price scam
Time to expose secret drug scam drug prices insurers american healthcare coupon
Drug copay assistance health insurance
